BMED vs HELX: Holdings Overlap & Returns
Over the year to Nov 13, 2026, BMED returned +25.4% to HELX's +22.6%; 12% of their weight is in the same names.
- Return gap
- +2.8 pts1 year to Nov 13, 2026: BMED ahead, total return
- Fee gap
- 0.05 ptsA year: BMED 0.55%, HELX 0.50%, per filings dated Nov 21, 2025 and Jul 27, 2026
- Overlap
- 12%Share of the two books held in common, holdings dated Nov 12, 2026 and Jun 30, 2026
- Net flow
- –Needs daily flows for both funds
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
BMED +25.4%, HELX +22.6%: BMED +2.8 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Cost to trade
Hypothetical. A $10,000 order in BMED costs about $11.50 one way and $23.00 in and out, at a median spread of 0.23%. The 0.23% spread is BMED’s 30-day median, from iShares (fund page).
Fees over time
Hypothetical. $10,000 in BMED for 10 years at 0.55% a year costs about $908 in fees and lost growth; HELX at 0.50% would cost $827. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
58% of BMED's weight is in S&P 500 companies and 42% is outside the index. Holdings as of Nov 12, 2026.
15% of HELX's weight is in S&P 500 companies and 85% is outside the index. Holdings as of Jun 30, 2026.
Key numbers
HELX costs 0.05 points a year less; their one-year returns differ by 2.8 points; HELX is 2.3 times larger.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +25.4% | +22.6% |
|---|---|---|
| Below its all-time high | 26.5%, high on Sep 7, 2021 | |
| What it tracks | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| Expense ratio | 0.55% | 0.50% |
| Net assets, as of Nov 12, 2026 | $15m | $34m |
| Holdings in common | 12% |
The numbers behind it
Net assets: $15m on Nov 13, 2026 for iShares Health Innovation Active ETF, and $34m on Nov 12, 2026 for Franklin Genomic Advancements ETF.
Holdings in common uses holdings dated Jun 30, 2026 and Nov 12, 2026.
What they share
By the books each fund has filed, BMED and HELX hold 12% of their money in the same securities at the same weight. Holdings dated Jun 30, 2026 and Nov 12, 2026.
half
12% in common
Held in common
Show all 12 holdings
| VERTEX PHARMACEUTICALS | 3.29% | 2.75% |
| NEUROCRINE BIOSCIENCES | 2.31% | 1.84% |
| CHARLES RIVER LABORATORIES INTERNA | 1.61% | 1.26% |
| GUARDANT HEALTH | 1.24% | 9.09% |
| TEMPUS AI CLASS A | 0.91% | 1.95% |
| THERMO FISHER SCIENTIFIC | 4.33% | 0.76% |
| IQVIA HOLDINGS INC | 3.58% | 0.75% |
| AXSOME THERAPEUTICS | 0.71% | 0.82% |
| AGILENT TECHNOLOGIES INC | 2.34% | 0.58% |
| DANAHER | 5.15% | 0.57% |
| PTC THERAPEUTICS | 0.44% | 1.46% |
| BRISTOL MYERS SQUIBB | 1.31% | 0.25% |
Only in BMED
Show all 8 holdings
| GILEAD SCIENCES | 5.80% |
| MODERNA | 5.52% |
| ABBVIE | 4.91% |
| EDWARDS LIFESCIENCES | 4.25% |
| BIOGEN | 3.70% |
| METTLER-TOLEDO INTERNATIONAL INC | 3.61% |
| MERCK & CO INC | 2.97% |
| ROCHE PS PAR AG | 2.85% |
Only in HELX
Show all 8 holdings
| NATERA INC | 7.46% |
| KRYSTAL BIOTECH INC | 6.33% |
| LIGAND PHARMACEUTICALS INC | 4.62% |
| ADAPTIVE BIOTECHNOLOGIES CORP | 3.99% |
| UNITED THERAPEUTICS CORP | 3.51% |
| BRIDGEBIO PHARMA INC | 3.50% |
| ELI LILLY & COMPANY | 2.95% |
| TWIST BIOSCIENCE CORP | 2.85% |
Side by side
Open the table
| Fund | iShares Health Innovation Active ETF · Holds 55 stocks in healthcare innovation and GLP-1, 58% of its weight in S&P 500 companies | Franklin Genomic Advancements ETF · Holds 61 stocks in healthcare innovation and GLP-1, 15% of its weight in S&P 500 companies |
| Issuer | iShares | Franklin |
| Theme | Healthcare innovation and GLP-1 | Healthcare innovation and GLP-1 |
| In the S&P 500 | 58.2% | 14.9% |
| Active share vs the S&P 500 | 95.6% | 97.2% |
| In the Nasdaq-100 | 13.8% | 7.5% |
| Holdings | 55 | 61 |
| Top ten, share of the fund | 44.1% | 47.1% |
| Expense ratio | 0.55% | 0.50% |
| Fee for the differing part | 0.58% | 0.51% |
| Total return, 1 year | +25.4% | +22.6% |
| vs its benchmark | not measured | not measured |
| Below its high | −2.7% | −26.5% |
| Net assets, BMED as of Nov 13, 2026 and HELX as of Nov 12, 2026 | $15m | $34m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the table
| 3 months | +12.9% | +5.0% |
|---|---|---|
| 6 months | +33.6% | +29.7% |
| 1 year | +25.4% | +22.6% |
| 3 years | +68.1% | +57.1% |
| Since launch (Not the same days: BMED Oct 2020 · HELX Feb 2020) | +42.8% | +78.8% |
About BMED
By weight, 58% of BMED's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 96%. The top ten holdings are 44% of the fund across 55 positions, as published by its issuer for Nov 12, 2026.
More
Over the year to Nov 13, 2026 the fund returned +25.4% with distributions reinvested.
About HELX
By weight, 15% of HELX's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 97%. The top ten holdings are 47% of the fund across 61 positions, as filed for Jun 30, 2026.
More
Over the year to Nov 13, 2026 the fund returned +22.6% with distributions reinvested. It sits 26.5% below its all-time high of Sep 7, 2021.
12% of the two portfolios are the same securities at the same weight.
Questions people ask
Do BMED and HELX hold the same stocks?
By their latest filings, 12% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, BMED against HELX, data as of Nov 13, 2026. https://etfiq.com/compare/themes/bmed-vs-helx
ETFIQ. (Nov 13, 2026). BMED against HELX. Retrieved from https://etfiq.com/compare/themes/bmed-vs-helx
[BMED against HELX (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/themes/bmed-vs-helx)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.